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Cancer and systemic inflammation: stage the
tumour and stage the host
D C McMillan*,1
1Medical School-University of Glasgow, Academic Unit of Surgery, Royal Infirmary, Glasgow G31 2ER, UK
In vol. 109, issue 01 of the BJC, Fox et al (2013) examined the
prognostic value of a range of markers of the systemic
inflammatory response in patients with advanced renal cancer–in
particular, whether such markers (albumin and neutrophil,
lymphocyte and platelet counts or their combinations) had
prognostic value in addition to an established scoring system
(MSCKCC). There was an improvement in overall risk strati-
fication (net reclassification of 26%) in patients when neutrophils,
platelets and the neutrophil lymphocyte ratio were included in the
scoring system. If confirmed in a similar clinical scenario, this will
be a useful clinical tool to improve treatment allocation.
The study by Fox et al (2013) is consistent with a large
volume of observational studies reporting that markers of the
systemic inflammatory response have independent prognostic
value in patients with a variety of cancers, including renal cancer
(Roxburgh and McMillan, 2010; Guthrie et al, 2013). Indeed, this
literature, whose lineage predates the genomic era, is compelling
through its consistency across tumour sites and clinical scenarios.
The importance of the present work is that it was carried out
within the context of a substantial randomised controlled trial and
well-defined entry criteria. Other markers of the systemic
inflammatory response or combinations such as C-reactive protein
and the GPS would have been of considerable interest (Roxburgh
and McMillan, 2010; McMillan, 2013). Nevertheless, as Fox et al
(2013) point out, the use of the simple components of a differential
white cell count to improve risk stratification in randomised trials
is of considerable interest, as these (at the least a white cell and
neutrophil count, Proctor et al, 2012) are routinely recorded in
almost all oncology trials. Therefore, there is a wealth of
randomised trial data available for post-hoc analysis to confirm
the clinical utility of such an approach.
The work of Fox et al (2013) should encourage further post-hoc
analysis of the systemic inflammatory response and outcome not
only in randomised trials of renal cancer but also in all oncology
trials. Such work will be key to our better understanding of the
relationship between cancer, inflammation and outcome in
patients with cancer.
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